Recently, the DESTINY-Breast04 study demonstrated the superior anti-tumor activity of T-DXd over physicians’choice in advanced breast cancer patients with HER2-low primary tumors (Modi et al., 2022). This evidence concerns the gene ERBB2 and neoplasm.